

DE GRUYTER

2018 · VOLUME 29 · ISSUE 6
ISSN 0792-6855 · e-ISSN 2191-0296

JOURNAL OF BASIC AND CLINICAL PHYSIOLOGY AND PHARMACOLOGY

EDITOR-IN-CHIEF
Michal Horowitz

DE
G

www.degruyter.com/jbcpp



Published by [De Gruyter](#)

Volume 32 Issue 4 - INTERNATIONAL CONFERENCE OF PHARMACY AND HEALTH SCIENCES: The 3rd JOINT CONFERENCE UNAIR - USM; Guest Editors: Suciati & Andang Miatmoko

July 2021

Issue of [Journal of Basic and Clinical Physiology and Pharmacology](#).

CONTENTS

[JOURNAL OVERVIEW](#)

[Accessible](#) June 25, 2021

Frontmatter

Page range: *i-ii*

[Cite this](#)

[Download PDF](#)

Original Articles

[Requires Authentication](#) June 25, 2021

Cost of illness of diabetes mellitus in Indonesia: a systematic review

Yohana Febriani Putri Peu Patty, Mufarrihah, Yunita Nita

Page range: *285-295*

[More ▾](#)

[Cite this](#)

[Requires Authentication](#) June 25, 2021

Social media health interventions to improve diabetes mellitus patient outcome: a systematic review

Riza Alfian, Umi Athiyah, Yunita Nita

Page range: *297-304*

[More ▾](#)

[Cite this](#)

[Requires Authentication](#) June 25, 2021

Developing pharmacokinetics – pharmacodynamics model of valproic acid syrup based on prediction of population pharmacokinetics parameter and seizure frequency in Indonesian pediatric epilepsy outpatients

I Komang Prawira Nata Nugraha, Anita Purnamayanti, I Gusti Ngurah Made Suwarba, Nani Parfati

Page range: *305-311*

[More ▾](#)

[Cite this](#)

[Requires Authentication](#) June 25, 2021

Acetylcholinesterase inhibitory activity of extract and fractions from the root of *Rauvolfia serpentina*(L.) Bth.ex Kurz

Suciati, Debora Poerwantoro, Aty Widawaruyanti, Kornkanok Ingkaninan

Page range: *313-317*

[More ▾](#)

[Cite this](#)

[Requires Authentication](#) June 25, 2021

Green tea and its active compound epigallocatechin-3-gallate (EGCG) inhibit neuronal apoptosis in a middle cerebral artery occlusion (MCAO) model

Abdulloh Machin, Imam Susilo, Djoko A. Purwanto

Page range: 319-325

More ▾

Cite this

Requires Authentication June 25, 2021

The effects of quercetin on nicotine-induced reward effects in mice

Mahardian Rahmadi, Dian Suasana, Silvy Restuning Lailis, Dinda Monika Nusantara Ratri, Chrismawan Ardianto

Page range: 327-333

More ▾

Cite this

Requires Authentication June 25, 2021

Resveratrol ameliorates physical and psychological stress-induced depressive-like behavior

Chrismawan Ardianto, Aniek Setiya Budiadin, I Nengah Budi Sumartha, Nurrahmi Nurrahmi, Mahardian Rahmadi, Junaidi Khotib

Page range: 335-340

More ▾

Cite this

Requires Authentication June 25, 2021

Translation and cross-cultural adaption of an instrument measuring patient's well-being under treatment for schizophrenia

Julaeha Julaeha, Umi Athiyah, Margarita Maria Maramis, Agus Sugianto, Andi Hermansyah

Page range: 341-347

More ▾

Cite this

Requires Authentication June 25, 2021

Quercetin promotes behavioral recovery and biomolecular changes of melanocortin-4 receptor in mice with ischemic stroke

Tuhfatul Ulya, Chrismawan Ardianto, Putri Anggreini, Aniek Setiya Budiadin, Dwi Setyawan, Junaidi Khotib

Page range: 349-355

More ▾

Cite this

Requires Authentication June 25, 2021

Knowledge and attitudes of healthcare professionals on prescribing errors

Desak Ketut Ernawati, Ida Ayu Alit Widhiartini, Endang Budiarti

Page range: 357-362

More ▾

Cite this

Requires Authentication June 25, 2021

Inhibition of Ras and STAT3 activity of 4-(tert-butyl)-N-carbamoylbenzamide as antiproliferative agent in HER2-expressing breast cancer cells

Aguslina Kirtishanti, Siswandono Siswodihardjo, I Ketut Sudiana, Desak G. A. Suprabawati, Aristika Dinaryanti

Page range: 363-371

More ▾

Cite this

Requires Authentication June 25, 2021

Predicting the molecular mechanism of glucosamine in accelerating bone defect repair by stimulating osteogenic proteins

Maria Apriliani Gani, Ahmad Dzulfikri Nurhan, Aniek Setiya Budiadin, Siswandono Siswodihardjo, Junaidi Khotib

Page range: 373-377

More ▾

Cite this

Requires Authentication June 25, 2021

Larvicidal toxicity and parasporal inclusion of native *Bacillus thuringiensis* BK5.2 against *Aedes aegypti*

Salamun, Fatimah, Ahmad Fauzi, Seling N. Praduwana, Ni'matuzahroh

Page range: 379-384

More ▾

Cite this

Requires Authentication June 25, 2021

Synthesis, ADMET predictions, molecular docking studies, and *in-vitro* anticancer activity of some benzoxazines against A549 human lung cancer cells

Melanny Ika Sulistyowaty, Retno Widyowati, Galih Satrio Putra, Tutuk Budiati, Katsuyoshi Matsunami

Page range: 385-392

More ▾

Cite this

Requires Authentication June 25, 2021

Thymoquinone and its derivatives against breast cancer with HER2 positive: *in silico* studies of ADMET, docking and QSPR

Adinda Adelia Wulandari, Achmad Aziz Choiri, Fitria, Tri Widiandani

Page range: 393-401

More ▾

Cite this

Requires Authentication June 25, 2021

Assessment of patient understanding of their conventional cardiac medicines and herbal prepared/derived products: preliminary survey and interviews with selected community-dwelling elderly patients in the Philippines

Jay P. Jazul, Trisha Michaela G. Arciga, Mary Angelie C. Ante, Danavin Gwyneth B. Berlin, Loise Francoise L. Ravana, Samantha A. Reyes, Jashanjit Singh

Page range: 403-413

More ▾

Cite this

Requires Authentication June 25, 2021

The development and validation of the health belief model questionnaire for measuring factors affecting adherence in the elderly with hypertension

Rodhiyatul Fithri, Umi Athiyah, Elida Zairina

Page range: 415-419

More ▾

Cite this

Requires Authentication June 25, 2021

Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients

Denny Ardianto, Suharjono, Soedarsono, Umi Fatmawati

Page range: 421-427

More ▾

Cite this

Requires Authentication June 25, 2021

Shallot skin profiling, computational evaluation of physicochemical properties, ADMET, and molecular docking of its components against P2Y12 receptor

Juni Ekowati, Kholidah Febriani, Itsna N. A. Yaqin, Adinda A. Wulandari, Indra H. Mulya, Kholis A. Nofianti, Achmad Syahrani

Page range: 429-437

More ▾

Cite this

Requires Authentication June 25, 2021

Analysis of HMGB-1 level before and after providing atorvastatin standard therapy in coronary artery disease patients with type-2 diabetes mellitus compared to without type-2 diabetes mellitus

Widya Handayani, Suharjono, Mohammad Yogiarto

Page range: 439-446

More ▾

Cite this

Requires Authentication June 25, 2021

Analysis of matrix metalloproteinase-9 levels among acute heart failure patients with ACE inhibitor therapy (Dr. Soetomo Regional General Hospital, Surabaya)

Ira Purbosari, Bambang Zubakti Zulkarnain, Muh Aminuddin, Umi Fatmawati

Page range: 447-451

More ▾

Cite this

Requires Authentication June 25, 2021

The correlation between self-related adherence, asthma-related quality of life and control of asthma in adult patients

Elida Zairina, Gesnita Nugraheni, Gusti Noorizka Veronika Achmad, Arie Sulistyarini, Yunita Nita, Arief Bakhtiar, Muhammad Amin

Page range: 453-458

More ▾

Cite this

Requires Authentication June 25, 2021

Providing counseling through home pharmacy care (HPC) for hemodialysis patients with hypertension in lowering blood pressure

Rahmiyati Daud, Bambang Subakti Zulkarnain, Ivan Virnanda Amu

Page range: 459-465

More ▾

Cite this

Requires Authentication June 25, 2021

Community knowledge and attitude in recognizing asthma symptoms and using medication for asthma attacks: a cross-sectional study

Arina Dery Puspitasari, Bindaria Mutmaina Prabawati, Alfian Nur Rosyid

Page range: 467-472

More ▾

Cite this

Requires Authentication June 25, 2021

A study of anticoagulant therapy in patients with coronary artery disease

Arina D. Puspitasari, Daniel Dwi Christiananta Salean, Didik Hasmono, Rudy Hartono, Meity Ardiana

Page range: 473-478

More ▾

Cite this

Requires Authentication June 25, 2021

The association of FKBP5 polymorphism with asthma susceptibility in asthmatic patients

Sura F. Alsaffar, Haider A. Rasheed, Jabbar H. Yenzeel, Haider F. Ghazi

Page range: 479-484

More ▾

Cite this

Requires Authentication June 25, 2021

Gastroprotective effect of fluvoxamine and ondansetron on stress-induced gastric ulcers in mice

Mahardian Rahmadi, Nily Su'aida, Pratiwi Yustisari, Wahyu Agung Dewaandika, Elma Oktavia Hanaratri, Mareta Rindang Andarsari, Sumarno, Toetik Aryani

Page range: 485-490

More ▾

Cite this

Requires Authentication June 25, 2021

Osteoblast iron genes: real time PCR and microarray hybridization approach under hyperoxia

Prihartini Widiyanti, Hartmut Kuehn, Soetjipto Soetjipto

Page range: 491-496

More ▾

Cite this

Requires Authentication June 25, 2021

Attenuation of hyperplasia in lung parenchymal and colonic epithelial cells in DMBA-induced cancer by administering *Andrographis paniculata* Nees extract using animal model

Aniek Setiya Budiadin, Ilham Bagus Sagitaras, Ika Putri Nurhayati, Nismatun Khairah, Khoirotin Nisak, Imam Susilo, Junaidi Khotib

Page range: 497-504

[More ▼](#)[Cite this](#)

Requires Authentication June 25, 2021

N-nitrosodiethylamine induces inflammation of liver in mice

Devy Maulidya Cahyani, Andang Miatmoko, Berlian Sarasitha Hariawan, Kusuma Eko Purwantari, Retno Sari

Page range: 505-510

[More ▼](#)[Cite this](#)

Requires Authentication June 25, 2021

AST/ALT levels, MDA, and liver histopathology of *Echinometra mathaei* ethanol extract on paracetamol-induced hepatotoxicity in rats

Angelica Kresnamurti, Dita Nurlita Rakhma, Amidasari Damayanti, Septiyan Dwi Santoso, Enggar Restryarto, Wifqi Hadinata, Iwan Sahrial Hamid

Page range: 511-516

[More ▼](#)[Cite this](#)

Requires Authentication June 25, 2021

Development, characterization, molecular docking, and *in vivo* skin penetration of coenzyme Q10 nanostructured lipid carriers using tristearin and stearyl alcohol for dermal delivery

Ni Luh Dewi Aryani, Siswandono Siswodihardjo, Widji Soeratri, Nadia Fitria Indah Sari

Page range: 517-525

[More ▼](#)[Cite this](#)

Requires Authentication June 25, 2021

The effect of *Camellia sinensis* (green tea) with its active compound EGCG on neuronal cell necroptosis in *Rattus norvegicus* middle cerebral artery occlusion (MCAO) model

Abdulloh Machin, Ramidha Syaharani, Imam Susilo, Muhammad Hamdan, Dyah Fauziah, Djoko Agus Purwanto

Page range: 527-531

[More ▼](#)[Cite this](#)

Requires Authentication June 25, 2021

Hepatoprotective effect of ethanolic extract of sugarcane (*Saccharum officinarum* Linn.) leaves

Ika P. Dewi, Rifdah B. Kwintana, Jihan U. Ulinnuha, Fadhillah Rachman, Fransiska M. Christianty, Diana Holiday

Page range: 533-540

[More ▼](#)[Cite this](#)

Requires Authentication June 25, 2021

Correlation between the exposure time to mobile devices and the prevalence of evaporative dry eyes as one of the symptoms of computer vision syndrome among Senior High School students in East Java, Indonesia

Rozalina Loebis, Bambang Subakti Zulkarnain, Nadhifa Zahra

Page range: 541-545

[More ▼](#)[Cite this](#)

Requires Authentication June 25, 2021

The effect of various high-fat diet on liver histology in the development of NAFLD models in mice

Mahardian Rahmadi, Ahmad Dzulfikri Nurhan, Eka Dewi Pratiwi, Devita Ardina Prameswari, Sisca Melani Panggono, Khoirotin Nisak, Junaidi Khotib

Page range: 547-553

[More ▼](#)[Cite this](#)

Requires Authentication June 25, 2021

Fabrication and characterization of bovine hydroxyapatite-gelatin-alendronate scaffold cross-linked by glutaraldehyde for bone regeneration

Samirah, Aniek Setiya Budiadin, Ferdiansyah Mahyudin, Junaidi Khotib

Page range: 555-560

[More ▼](#)[Cite this](#)

[More](#) [Cite this](#)
Requires Authentication June 25, 2021

Health related quality of life among postmenopausal woman with hormone responsive HER2- breast cancer in Indonesia

Ria Etikasari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati Taroeno-Hariadi

Page range: 561-565

[More](#)

[Cite this](#)

Requires Authentication June 25, 2021

Gender differences in the blood glucose type 2 diabetes patients with combination rapid and long acting insulin therapy

Dinda M. N. Ratri, Arina D. Puspitasari, Cahyo W. Nugroho, Budi Suprapti, Suharjono, Christoper P. Alderman

Page range: 567-570

[More](#)

[Cite this](#)

Requires Authentication June 25, 2021

Correlation of dietary iron intake and serum iron with thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels in adult hyperthyroid patients

Utami Harjantini, Yulia Lanti Retno Dewi, Diffah Hanim, Ida Nurwati

Page range: 571-576

[More](#)

[Cite this](#)

Requires Authentication June 25, 2021

The effect of pillbox use and education by pharmacist toward medication adherence in diabetes mellitus patients in a Primary Health Care Center in Mataram

Mahacita Andanalusia, Yunita Nita, Umi Athiyah

Page range: 577-582

[More](#)

[Cite this](#)

Requires Authentication June 25, 2021

Variation concentration effect of propyleneglycol, glycerin, and polyethyleneglycol 400 to physical properties and dissolution rate of loratadine liquisolid tablet

Mikhania Christiningtyas Eryani, Esti Hendradi, Siswandono

Page range: 583-587

[More](#)

[Cite this](#)

Requires Authentication June 25, 2021

Role of *Centella asiatica* and ceramide in skin barrier improvement: a double blind clinical trial of Indonesian batik workers

Sylvia Anggraeni, Menul Ayu Umborowati, Damayanti Damayanti, Anang Endaryanto, Cita Rosita Sigit Prakoeswa

Page range: 589-593

[More](#)

[Cite this](#)

Requires Authentication June 25, 2021

Secondary metabolite and antipyretic effects of Maja (*Crescentia cujete* L.) in fever-induced mice

Teodhora, Munawarohthus Sholikha, Asniatul Ania, Ika Maruya Kusuma

Page range: 595-601

[More](#)

[Cite this](#)

Requires Authentication June 25, 2021

Hydration effect on kidney function and serum electrolyte in children with tumor lysis syndrome (TLS) and risk of TLS

Yulistiani, Claudia Tiffany, I. Dewa Gede Ugrasena, Mariyatul Qibtiyah

Page range: 603-609

[More](#)

[Cite this](#)

Requires Authentication June 25, 2021

Drug utilization study and cost analysis of adult β -thalassemia major patient therapy at Dr. Soetomo General Hospital Surabaya

Hasna Qatrunnada, Suharjono, Siprianus Ugroseno Yudho Bintoro, Siti Wahyuni

Page range: 611-616

More ▾

Cite this

Requires Authentication June 25, 2021

The role of hyperbaric oxygen to platelet aggregation in noninsulin-dependent diabetes mellitus (NIDDM)

Prihartini Widiyanti, Purnomo Suryohudoyo

Page range: 617-621

More ▾

Cite this

Requires Authentication June 25, 2021

Cocrystal formation of loratadine-succinic acid and its improved solubility

Dwi Setyawan, Firdaus Rendra Adyaksa, Hanny Lystia Sari, Diajeng Putri Paramita, Retno Sari

Page range: 623-630

More ▾

Cite this

Requires Authentication June 25, 2021

The role of chondroitin sulfate to bone healing indicators and compressive strength

Herry Wibowo, Prihartini Widiyanti, Syaifullah Asmiragani

Page range: 631-635

More ▾

Cite this

Requires Authentication June 25, 2021

The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice

Jamal Nasser Saleh Al-mamari, Mahardian Rahmadi, Sisca Melani Panggono, Devita Ardina Prameswari, Eka Dewi Pratiwi, Chrismawan Ardianto, Santhra Segaran Balan, Budi Suprapti

Page range: 637-644

More ▾

Cite this

Requires Authentication June 25, 2021

Analysis of stress ulcer prophylaxis drug regimentation in surgical patients

Dhani Wijaya, Suharjono, Fendy Matulatan, Elfri Padolo

Page range: 645-649

More ▾

Cite this

Requires Authentication June 25, 2021

The stability and irritability study of the chitosan-Aloe vera spray gel as wound healing

Dini Retnowati, Retno Sari, Esti Hendradi, Septiani Septiani

Page range: 651-656

More ▾

Cite this

Requires Authentication June 25, 2021

Effectiveness of citicoline in pediatric patients with refractive amblyopia in Surabaya, East Java, Indonesia

Rozalina Loebis, Bambang Subakti Zulkarnain, Fitri Amalia Siswanto

Page range: 657-661

More ▾

Cite this

Requires Authentication June 25, 2021

The thermodynamic study of *p*-methoxycinnamic acid inclusion complex formation, using β -cyclodextrin and hydroxypropyl- β -cyclodextrin

Dewi Isadiartuti, Noorma Rosita, Juni Ekowati, Achmad Syahrani, Toetik Ariyani, M. Ainur Rifqi

Page range: 663-667

[More ▾](#)[Cite this](#)

Requires Authentication June 25, 2021

The effect of chitosan type and drug-chitosan ratio on physical characteristics and release profile of ketoprofen microparticles prepared by spray drying

Muhammad A. S. Rijal, Hanah Masitah, Fanny Purvitasari, Retno Sari

Page range: 669-673

[More ▾](#)[Cite this](#)

Requires Authentication June 25, 2021

The maximum dose and duration in the therapy single use methotrexate to achieve remission by rheumatoid arthritis patients through disease activity score 28 (DAS28)

Anisyah Achmad, Tika Yasmin Rahmayanti, Bagus Putu Putra Suryana

Page range: 675-680

[More ▾](#)[Cite this](#)

Accessible June 25, 2021

Knowledge, attitudes, and practices (KAP) towards COVID-19 among university students in Pakistan: a cross-sectional study

Shah Faisal, Junaidi Khotib, Elida Zairina

Page range: 681-686

[More ▾](#)[Cite this](#)[Download PDF](#)

Requires Authentication June 25, 2021

The impact of glutaraldehyde on the characteristics of bovine hydroxyapatite-gelatin based bone scaffold as gentamicin delivery system

Aniek Setiya Budiadin, Maria Apriliani Gani, Chrismawan Ardianto, Samirah, Sahrati Yudiaprijah Daeng Pattah, Fitroh Mubarakah, Junaidi Khotib

Page range: 687-691

[More ▾](#)[Cite this](#)

Requires Authentication June 25, 2021

Analysis of the use of antibiotics profile and factors of surgical site infections study on digestive and oncology surgeries

Lisa Narulita, Suharjono, Kuntaman, Mohammad Akram

Page range: 693-700

[More ▾](#)[Cite this](#)

Requires Authentication June 25, 2021

Second internal transcribed spacer (ITS-2) as genetic marker for molecular characterization of *Sarcoptes scabiei* in rabbits from several areas of East Java, Indonesia

Nunuk Dyah Retno Lastuti, Nur Rusdiana, Poedji Hastutiek

Page range: 701-705

[More ▾](#)[Cite this](#)

Requires Authentication June 25, 2021

Design of gossypetin derivatives based on naturally occurring flavonoid in *Hibiscus sabdariffa* and the molecular docking as antibacterial agents

Nuzul W. Diyah, Isnaeni, Shabrina W. Hidayati, Bambang T. Purwanto, Siswandono

Page range: 707-714

[More ▾](#)[Cite this](#)

Requires Authentication June 25, 2021

Discovery of new targeting agents against GAPDH receptor for antituberculosis drug delivery

Muhammad Amirul Asyraf Noh, Siti Sarah Fazalul Rahiman, Habibah A Wahab, Amirah Mohd Gazzali

Page range: 715-722

[More ▾](#)[Cite this](#)

🔒 Requires Authentication June 25, 2021

The effect of red passion fruit (*Passiflora edulis* Sims.) fermentation time on its activity against Extended Strain Methicillin-Resistant (ESBL) *Escherichia coli* and Methicillin-Resistant *Staphylococcus aureus* (MRSA)

Iif Hanifa Nurrosyidah, Ni Made Mertaniasih, Isnaeni

Page range: 723-727

[More ▾](#)[Cite this](#)

🔒 Requires Authentication June 25, 2021

Antibiotic use on acute respiratory tract infection nonpneumonia and nonspecific diarrhea in Primary Health Care Centre in Banjarbaru City, South Kalimantan, Indonesia

Rizky Liestya Wardani, Suharjono, Kuntaman, Agus Widjaja

Page range: 729-735

[More ▾](#)[Cite this](#)

🔒 Requires Authentication June 25, 2021

Screening of anti-HIV activities in ethanol extract and fractions from *Ficus fistulosa* leaves

Siti Qamariyah Khairunisa, Dwi Wahyu Indriati, Lidya Tumewu, Aty Widyawaruyanti, Nasronudin Nasronudin

Page range: 737-742

[More ▾](#)[Cite this](#)

🔒 Requires Authentication June 25, 2021

The characteristics of lactic acid bacteria isolated from fermented food as potential probiotics

Victoria Yulita Fitriani, Budi Suprapti, Muhammad Amin

Page range: 743-749

[More ▾](#)[Cite this](#)

🔒 Requires Authentication June 25, 2021

Profile of *gyrA* gene mutation in clinical isolate of levofloxacin resistant *Escherichia coli*

Alifia Risma Fahmi, Suharjono, Kuntaman

Page range: 751-754

[More ▾](#)[Cite this](#)

🔒 Requires Authentication June 25, 2021

Antimicrobial activity of *Centella asiatica* and *Gigantochloa apus*

Siti Mudaliana

Page range: 755-759

[More ▾](#)[Cite this](#)

🔒 Requires Authentication June 25, 2021

Drug-related problems of antibiotic use in gastroenteritis related to patient therapy outcomes at Universitas Gadjah Mada Hospital

Fivy Kurniawati, Nanang Munif Yasin, Farida Aulia, Gidfrie Vinanda Krishna

Page range: 761-766

[More ▾](#)[Cite this](#)

🔒 Requires Authentication June 25, 2021

The impact of suitability of empirical antibiotics use on therapeutic outcome of respiratory tract infection patients at inpatient wards of Universitas Gadjah Mada Academic Hospital

Fivy Kurniawati, Nanang Munif Yasin, Safina Nur Azizah, Silvia Ayu Purbaningtyas

Page range: 767-771

[More ▾](#)[Cite this](#)

Requires Authentication June 25, 2021

Genetic profile mutation *rpoB* in clinical isolate of rifampicin-resistant *Staphylococcus aureus*

Risa Zulfiana, Suharjono, Kuntaman

Page range: 773-776

More ▾

Cite this

Requires Authentication June 25, 2021

Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy

Novan Yusuf Indra Pratama, Bambang Subakti Zulkarnain, Soedarsono, Umi Fatmawati

Page range: 777-781

More ▾

Cite this

Requires Authentication June 25, 2021

Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: a retrospective study

Wenny Putri Nilamsari, Muhammad Fajar Rizqi, Natasya Olga Regina, Prastuti Asta Wulaningrum, Umi Fatmawati

Page range: 783-787

More ▾

Cite this

Requires Authentication June 25, 2021

Analysis of prophylactic antibiotic use and risk factor of postoperative infection in urological surgery patients

Ratri Rokhani, Suharjono, Kuntaman, Mohammad Akram

Page range: 789-794

More ▾

Cite this

Requires Authentication June 25, 2021

Molecular docking studies of *Nigella sativa* L and *Curcuma xanthorrhiza* Roxb secondary metabolites against histamine N-methyltransferase with their ADMET prediction

Ahmad Dzulfikri Nurhan, Maria Apriliani Gani, Aniek Setiya Budiadin, Siswando Siswodihardjo, Junaidi Khotib

Page range: 795-802

More ▾

Cite this

Requires Authentication June 25, 2021

Prediction of compounds with antiosteoporosis activity in *Chrysophyllum cainito* L. leaves through *in silico* approach

Burhan Ma'arif, Hilwa Fitri, Nisfatul Lailatus Saidah, Luqman Alfani Najib, Achmad Hamdan Yuwafi, Ria Ramadhani Dwi

Atmaja, Fidia Rizkiah Inayatillah, Meilina Ratna Dianti, Hening Laswati, Mangestuti Agil

Page range: 803-808

More ▾

Cite this

Requires Authentication June 25, 2021

Phyllanthin and hypophyllanthin, the isolated compounds of *Phyllanthus niruri* inhibit protein receptor of corona virus (COVID-19) through *in silico* approach

Honey Dzikri Marhaeny, Aty Widyawaruyanti, Tri Widiandani, Achmad Fuad Hafid, Tutik Sri Wahyuni

Page range: 809-815

More ▾

Cite this

Requires Authentication June 25, 2021

***Cratoxylum sumatranum* stem bark exhibited antimalarial activity by Lactate Dehydrogenase (LDH) assay**

Lidya Tumewu, Fendi Yoga Wardana, Hilkatul Ilmi, Adita Ayu Permanasari, Achmad Fuad Hafid, Aty Widyawaruyanti

Page range: 817-822

More ▾

Cite this

Requires Authentication June 25, 2021

Endophytic fungi inhabiting *Physalis angulata* L. plant: diversity, antioxidant, and antibacterial activities of their ethyl acetate extracts

Kartika Dyah Palupi, Muhammad Ilyas, Andria Agusta

Page range: 823-829

More ▾

Cite this

Requires Authentication June 25, 2021

Exploration of several plants from Baung Forest on bone formation cell models

Retno Widyowati, Neny Purwitasari, Rice Disi Oktarina, Wiwied Ekasari, Saarah Khairunnisa, Hsin-I. Chang

Page range: 831-837

More ▾

Cite this

Requires Authentication June 25, 2021

In vitro antimalarial activity of *Garcinia parvifolia* Miq. Stem extracts and fractions on *Plasmodium falciparum* lactate dehydrogenase (LDH) assay

Marsih Wijayanti, Hilkatul Ilmi, Einstenia Kemalahayati, Lidya Tumewu, Fendi Yoga Wardana, Suciati, Achmad Fuad Hafid, Aty Widyawaruyanti

Page range: 839-844

More ▾

Cite this

Requires Authentication June 25, 2021

Antioxidant and antiviral potency of *Begonia medicinalis* fractions

Muhammad Sulaiman Zubair, Siti Qamariyah Khairunisa, Evi Sulastri, Ihwan, Agustinus Widodo, Nasronudin, Ramadanil Pitopang

Page range: 845-851

More ▾

Cite this

Requires Authentication June 25, 2021

Artocarpus sericarpus stem bark contains antimalarial substances against *Plasmodium falciparum*

Lidya Tumewu, Lutfah Qurrota A'yun, Hilkatul Ilmi, Achmad Fuad Hafid, Aty Widyawaruyanti

Page range: 853-858

More ▾

Cite this

Requires Authentication June 25, 2021

Formulation and characterization of *Eleutherine palmifolia* extract-loaded self-nanoemulsifying drug delivery system (SNEDDS)

Rahmi Annisa, Mochammad Yuwono, Esti Hendradi

Page range: 859-865

More ▾

Cite this

Requires Authentication June 25, 2021

Analytical method for the determination of curcumin entrapped in polymeric micellar powder using HPLC

Helmy Yusuf, Nina Wijiani, Rizka Arifa Rahmawati, Riesta Primaharinastiti, M. Agus Syamsur Rijal, Dewi Isadiartuti

Page range: 867-873

More ▾

Cite this

Requires Authentication June 25, 2021

Challenges in the provision of natural medicines by community pharmacists in East Java Province, Indonesia

Hanni P. Puspitasari, Dhita Fatmaningrum, Sa'adatus Zahro, Shofi Salsabila, Zulfia A. Rizqulloh, Ana Yuda, Mufarrihah, Anila I. Sukorini, Neny Purwitasari

Page range: 875-880

More ▾

Cite this

Requires Authentication June 25, 2021

In vitro and in silico analysis of phytochemical compounds of 96% ethanol extract of semanggi (*Marsilea crenata* Presl.) leaves as a bone formation agent

Agnis P.R. Aditama, Burhan Ma'arif, Hening Laswati, Mangestuti Agil

Page range: 881-887

More ▾

Cite this

Requires Authentication June 25, 2021

Inhibitory activity of *Urena lobata* leaf extract on alpha-amylase and alpha-glucosidase: *in vitro* and *in silico* approach

Yudi Purnomo, Juliah Makdasari, Faiqoh Inayah Fatahillah

Page range: 889-894

More ▾

Cite this

Case Report

Requires Authentication June 25, 2021

Effect of hydrocortisone on hypocortisolism caused by pituitary adenoma

Niswah N. Qonita, Hanik B. Hidayati

Page range: 895-898

More ▾

Cite this

Search journal



This issue All issues

Contact us

Customer Service
Human Resources
Press
Contacts for authors

Career

How to join us
Current Vacancies
Working at De Gruyter

Open Access

Articles
Books
Funding & Support

For Authors

Publish your book
Publish your journal article
Abstracting & Indexing

For Libraries & Trade Partners

Electronic Journals
Ebooks
Databases & Online Reference
Metadata

Our Partner Publishers

Rights & Permissions

Repository Policy
Free Access Policy

About De Gruyter

De Gruyter Foundation
Our locations

Help/FAQ
Privacy Policy
Terms & Conditions
Legal Notice

JOURNAL OF BASIC AND CLINICAL PHYSIOLOGY AND PHARMACOLOGY

EDITOR-IN-CHIEF

Ugo Oliviero, Naples, Italy

DEPUTY EDITOR

Alberto M. Marra, Naples, Italy/Heidelberg, Germany

EDITORIAL BOARD

Giorgio Bosso, Naples, Italy

Ewelyine Biskup, Basel, Switzerland/ Shanghai, China

Pablo Demelo-Rodriguez, Madrid, Spain

Antonio Valvano, Legnano, Italy

Theodor Voisou, Bucarest, Romania

Andrei Voisou, Bucarest, Romania

Lorenzo Falsetti, Ancona, Italy

Valeria Raparelli, Ferrara, Italy

Ieva Ruza, Riga, Latvia

Mariarosaria De Luca, Naples, Italy

Andrea Salzano, Leicester, UK

Antonio Cittadini, Naples, Italy

Salvatore Torrisi, Catania, Italy

Leonardo Bencivenga, Naples, Italy

Gilda Varricchi, Naples, Italy

Domenico Sambataro, Catania, Italy

Raffaella Spina, Baltimore, USA

Francesca Vinchi, New York, USA,

Roberta D'Assante, Naples, Italy

DE GRUYTER

ABSTRACTED/INDEXED IN Baidu Scholar · Case · Chemical Abstracts Service (CAS): CAplus · Chemical Abstracts Service (CAS) - SciFinder · CINAHL · CNKI Scholar (China National Knowledge Infrastructure) · CNPIEC: cnpLINKer · Dimensions · EBSCO (relevant databases) · EBSCO Discovery Service · Embase · FSTA: Food Science & Technology Abstracts · Genamics JournalSeek · Google Scholar · Japan Science and Technology Agency (JST) · J-Gate · JournalGuide · JournalTOCs · KESLI-NDSL (Korean National Discovery for Science Leaders) · Medline · Meta · Microsoft Academic · MyScienceWork · Naver Academic · Naviga (Softweco) · Primo Central (ExLibris) · ProQuest (relevant databases) · Publons · PubMed · PubsHub · QOAM (Quality Open Access Market) · ReadCube · Reaxys · SCImago (SJR) · SCOPUS · Semantic Scholar · Sherpa/RoMEO · Summon (ProQuest) · TDNet · Text Mining · Ulrich's Periodicals Directory/ulrichsweb · WanFang Data · Web of Science: Biological Abstracts; BIOSIS Previews · WorldCat (OCLC)

e-ISSN 2191-0286

All information regarding notes for contributors, subscriptions, Open access, back volumes and orders is available online at www.degruyter.com/jbcpp.

RESPONSIBLE EDITOR Prof. Ugo Oliviero, Department of Translational Medical Sciences, Federico II University, Via pansini 5, Naples, Campania, 80131 Italy, e-mail: ugo.oliviero@unina.it

PUBLISHER Walter de Gruyter GmbH, Berlin/Boston, Genthiner Straße 13, 10785 Berlin, Germany

JOURNAL MANAGER Katharina Appelt, De Gruyter, Genthiner Str. 13, 10785 Berlin, Germany, Tel.: +49 (0)30 260 05-325, e-mail: jbcpp.editorial@degruyter.com

RESPONSIBLE FOR ADVERTISEMENTS Kevin Göthling, De Gruyter, Genthiner Straße 13, 10785 Berlin, Germany, Tel.: +49 (0)30 260 05-170, e-mail: anzeigen@degruyter.com

© 2021 Walter de Gruyter GmbH, Berlin/Boston, Germany

TYPESETTING TNQ Technologies, Chennai, India

Julaeha Julaeha, Umi Athiyah, Margarita Maria Maramis, Agus Sugianto and
Andi Hermansyah*

Translation and cross-cultural adaption of an instrument measuring patient's well-being under treatment for schizophrenia

<https://doi.org/10.1515/jbcpp-2021-0002>

Received January 2, 2021; accepted March 8, 2021

Abstract

Objectives: The Subjective Well-Being under Neuroleptic (SWN) Scale is a self-rating scale measuring the well-being of patients with schizophrenia under antipsychotic drug treatment. The instrument has been globally used, with issues regarding the well-being assessment scale across different cultures, patient characteristics, and country-setting remains a controversy. This study aimed to translate and culturally adapt the SWN scale into the Indonesian version (Indonesian Modified SWN or IM-SWN) and evaluate its validity and reliability.

Methods: The SWN instrument was translated and culturally adapted following internationally accepted procedures, including forward translation, expert panel review, backward-translation, pretesting and cognitive interviewing, and psychometric analysis for the final version of the scale. The translated instrument was tested on 108 schizophrenia patients. The instrument's validity and reliability were assessed using Pearson's correlation and Cronbach's Alpha coefficient. Additional analysis for the socio-demographic and psychometric properties of the patient was also conducted.

Results: The range of IM-SWN total score between 30 and 112. IM-SWN was found to have a high-reliability coefficient (0.897), and the internal consistency values of each question item ranged between 0.885 and 0.910. The results also showed a high correlation between five order factors (Physical functioning, mental functioning, self-control, emotional regulation, and social integration), with a total score of between 0.768 and 0.885.

Conclusions: This study highlighted that the IM-SWN is a valid and reliable instrument for measuring well-being among the Indonesian population with schizophrenia.

Keywords: antipsychotics; mental health; schizophrenia; subjective well-being; translation.

Introduction

Within the past 10 years, there has been shifting focus on measuring patients' quality of life towards evaluating a complex set of Economic, Clinical and Humanistic Outcome (ECHO) based on patients' subjective experiences [1]. The World Health Organization (WHO) described the quality of life as "individual perceptions of their position in life in the context of the culture and value system in which they live, and in relation to their goals, expectation, standards, and concerns" [3]. The definition highlights the need to maintain quality of life in the longer term, which might be an issue for patients who received long-term therapy, such as schizophrenia.

Poor patient compliance, service disengagement, and comorbid disorder are some features attributed to the low quality of life in a patient with schizophrenia [2]. Moreover, the patient's condition might even be worsened with disabilities, severe mental illness, and a plethora of disruption both socially and individually to the patient's life [4]. Therefore, it is not surprising that treatment for patients with schizophrenia may comprise understanding the patient's autonomy, right, and opinion as an adjunct to pharmacological treatment [4]. The long-term goal for patients with schizophrenia is improved initial response of therapy, decreased level of severity, and improved social

*Corresponding author: Andi Hermansyah, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia, Phone: +62315933150, E-mail: andi-h@ff.unair.ac.id. <https://orcid.org/0000-0002-9716-3126>

Julaeha Julaeha, Faculty of Pharmacy, Universitas 17 Agustus 1945 Jakarta, Jakarta, Indonesia; and Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. <https://orcid.org/0000-0002-8807-5175>

Umi Athiyah, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

Margarita Maria Maramis, Dr. Soetomo Academic Hospital, Surabaya, Indonesia; and Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Agus Sugianto, Center for Public Mental Health, Universitas Gadjah Mada, Yogyakarta, Indonesia

functioning and life quality. This is why measuring the quality of life in such patients is challenging.

A number of published studies focused on evaluating the quality of life from the physician perspective; for instance, the Quality of Life Scale (QLS) [6–13]. However, this might be insufficient as patients with schizophrenia generally receive antipsychotic medication, which has not been included in such measurement. Therefore, compliance towards antipsychotic treatment is essential to be included within the full spectrum of measuring patients' quality of life [5]. Recently, there has been a change of interest in measuring the patient's well-being, such as the Subjective Well-being under neuroleptics (SWN) scale. The Subjective Well-being under neuroleptics (SWN) scale is an example of the questionnaire to assess the patient's quality of life [14, 15]. This questionnaire has been utilized in various current studies [16–19]. The SWN is translated into more than 40 languages [20–27]. However, there is no available scale developed in the Indonesian language despite the significant population of Indonesians suffering from schizophrenia. The presence of such scale may demonstrate its significance to the treatment in Indonesia. The objective of this study is to measure the validity and reliability of the Indonesian version SWN questionnaire as part of the translation and adaptation of the instrument.

Materials and methods

Study design

Ethics approval was obtained from the Research Ethics Committee of Menur Mental Hospital, Surabaya, East Java (No. 070/7556/305/2019) which was also the site for this study. From the electronic mail correspondence on 24 December 2019, the research team gained official permission and confirmation from the SWN scale developer to develop the scale into Indonesian. The study was a cross-sectional design with participants, which were purposively sampled.

Participants

Outpatient schizophrenia patients were selected for this study. The inclusion criteria are patients with schizophrenia, aged 18 or older, consented to participate in the study and a patient who has no vision problems. The exclusion criteria are patients who suffered from other psychiatric illness and patients diagnosed with brain dysfunction or cognitive impairment. Informed consent was acquired from all participants prior to beginning the study. Participants were involved only after they signed informed consent. All researchers ensured participant data confidentiality and compliance with the Declaration of Helsinki. The total participants were 108 schizophrenia patients

who completed the study; they either participated in online or offline interviews.

Instrument

The original subjective well-being under neuroleptic treatment scale (SWN) consisted of 38 statements and later modified by the author in a shorter form consisted of 20 statements, each consists 10 positive statements and 10 negative statements, respectively [14, 15]. The patients filled out this questionnaire based on their understanding of health status, symptoms of psychosis, the effect on the antipsychotic, and nonmedical aspect through the preceding 7 days [15].

This study applied 6-point Likert scale from SWN short form (1–6). The total score varies from 20 to 120 points, and the higher score indicates greater well-being. There are five domains of SWN: physical function (PF), mental function (MF), self-control (SC), emotional regulation (ER), and social integration (SI) with each domain consisted of four statements. The score ranges for each domain from 4 points (worst) to 24 points (best) [15].

Translation, cross-cultural adaption and SWN validation in Indonesian language

This study followed the Principles of Good Practice for the Translation and Culture Adaption Process to adapt the SWN short form into Indonesian version [28]. The original questionnaire was translated into Indonesian by a sworn translator and reversed back into English translation by a different sworn translator blindfolded to the original version.

Both versions have been analyzed and reviewed to be as accurate as possible to the original English version by three authors (JJ, UA, and AH), who are competent and fluent in Indonesian and English. The final Indonesian-language version was achieved through consensus among authors. The comprehensiveness of every part and items in this form was then examined by an expert panel involving one psychiatrist, two mental health pharmacists, and one schizophrenia caregiver from Indonesian Community Care for Schizophrenia (Figure 1).

Data analysis

We used the IBM SPSS for windows version 24.0 for data analysis, and a $p < 0.05$ was considered statistically significant. Descriptive analysis was presented for characteristics of participants and psychometric properties of SWN Indonesian version. For reliability analysis, the coefficient of internal consistency (Cronbach's Alpha) which is calculated based on the variance of each item, was utilized. The Pearson correlation coefficient was calculated to test the construct validity. Analysis Moment of Structural (AMOS) program was used for confirmatory factor analysis (CFA).

Results

Table 1 reveals that male patients were major respondents (57%), the age ranged from 31–49 years were dominant




Figure 1: Flowchart of adaption of SWN into Indonesian version.

(65%) and most of the patients were single (60%), 37% have secondary education, and half of them were not a worker. The prescription frequency for antipsychotic as monotherapy was low (22%), with the majority of patients being on antipsychotics polypharmacy. Table 2 shows the lowest total score of SWN was 30, the highest total score of SWN was 112, and the mean of SWN scores were 82.88 (SD=16.745). The mean scores of self-control were highest (17.83; SD=3.266), followed by emotional-regulation (17.13; SD=4.501), social-integration (16.75; SD=4.752), mental function (15.95; SD=3.933), and physical function (15.21; SD=3.671).

The internal consistency among the Indonesian version items, as shown by Cronbach’s coefficient alpha was high (0.897). This result also showed high internal consistency values of the items, which varied between 0.885 and 0.910 (Table 3). The construct validity of the scale was measured using Pearson correlations analysis. The construct validity for each domain and its total score between 0.768 and 0.885 (Table 4). A confirmatory factor analysis was conducted demonstrated comparative fit analysis index (CFI), the goodness of fit analysis index (GFI), root mean square of approximation (RMSEA) were 0.872 and 0.787, also root mean square error of approximation (RMSEA) were 0.79, respectively (Figure 2).

Table 1: Characteristic of respondent (n=108).

Characteristics	n	%
Gender		
Male	62	57
Female	46	43
Age, year		
18–30	25	23
31–49	70	65
50–65	11	10
>65	2	2
Marital status		
Single	65	60
Married	32	30
Divorced	11	10
Regional		
East Java and Bali	57	53
Yogyakarta	7	6
Central Java	22	20
West Java and Banten	11	10
Jakarta	6	6
Sumatra and Borneo	5	5
Educational level		
Elementary school	6	6
Junior high school	12	11
Senior high school	40	37
Diploma	15	14
Undergraduate or higher	35	32
Occupation		
Full time	31	29
Part time	30	28
Not worker	47	43
Duration of treatment, year		
<1	11	10
1–5	39	36
6–10	24	22
>10	34	32
Number of antipsychotics		
Monotherapy	24	22
2 antipsychotics	46	43
≥3 antipsychotics	38	35

Table 2: Psychometric properties of the Indonesian version scale (n=108).

	Minimum	Maximum	Mean	SD
Total score	30	112	82.88	16.745
Physical function	4	24	15.21	3.671
Mental function	4	24	15.95	3.933
Self-control	8	24	17.83	3.266
Emotional regulation	4	24	17.13	4.501
Social integration	4	24	16.75	4.752

Table 3: Cronbach's alpha values of reliability tests (n=108).

Item	Minimum	Maximum	Mean	SD	Cronbach's α if item deleted
Q1	1	6	4.18	1.420	0.893
Q2	1	6	4.47	1.300	0.889
Q3	1	6	4.48	1.308	0.889
Q4	1	6	4.06	1.693	0.885
Q5	1	6	3.63	1.754	0.910
Q6	1	6	3.82	1.668	0.885
Q7	1	6	4.25	1.340	0.902
Q8	1	6	4.53	1.329	0.889
Q9	1	6	3.31	1.412	0.891
Q10	1	6	4.21	1.565	0.887
Q11	1	6	3.56	1.474	0.890
Q12	1	6	3.99	1.556	0.890
Q13	1	6	4.07	1.477	0.889
Q14	1	6	4.32	1.509	0.889
Q15	1	6	4.94	1.035	0.895
Q16	1	6	3.80	1.605	0.889
Q17	1	6	3.66	1.542	0.889
Q18	1	6	4.28	1.310	0.897
Q19	1	6	4.73	0.943	0.898
Q20	1	6	4.57	1.320	0.886

Table 4: Pearson correlation for each domain of the Indonesian version scale (n=108).

	Pearson correlations	Sig. (2-tailed)
Physical function	0.798**	0.000
Mental function	0.794**	0.000
Self-control	0.768**	0.000
Emotional regulation	0.885**	0.000
Social integration	0.884**	0.000

Pearson product moment correlation coefficients: small (0.10–0.29), medium (0.30–0.49), and large (>0.50); **p<0.01.

Discussion

Disease-specific quality of life and well-being instruments are more sensitive to treatment effects measure than generic instruments [29–31]. Patient report measurements may provide the most direct access to the individual's perceptions domain. The Indonesian version of SWN scale was created as an instrument for research and clinical practice to assess the subjective well-being in different dimensions of patients suffering from schizophrenia disorder medicated with antipsychotics.

The findings of this study showed acceptable internal consistency evidence, as well as construct validity for the modified scale. The modified scale's internal consistency

was found not significantly differ from the original version (Cronbach's alpha=0.92), and the subscale reliabilities ranged from 0.818–0.852 [15]. It could, therefore, be concluded that the Indonesian version of SWN scale is internally consistent. Additionally, the principal component analysis results indicated that the Indonesian version is relatively similar to the original version [15]. In addition, the finding shows the correlation score is higher than SWN Turkish version (0.52–0.63) and Estonian version (0.55–0.68) [23, 24].

Recovery condition or functional remission in schizophrenia was determined as the attainment of three criteria: i) the ability to gain a job or voluntary work or to be an active student or head of a family with an engaged partner; (ii) independent life, single or with groups or spouse; and (iii) social connection with more than two contacts in the last 4 weeks or possessing a partner or spouse [32, 33]. Adequate subjective well-being can be used for an early outcome prediction and treatment planning [34]. The criterion of adequate subjective well-being was shown by SWN total score ≥ 80 points [32]. This study's results indicated more than half of patients with schizophrenia in functional remission condition based on these criteria.

This study shows no difference in the SWN score among participants based on different types and number of antipsychotics. Despite the controversy related to the impact of antipsychotics treatment on subjective well-being [14], this study offers the potential use of the Indonesian version as a scale to measure the subjective well-being of schizophrenia patients.

A cautious interpretation of the result of this study is required due to several methodological limitations. Firstly, this study sample size might not reflect and represent patients' overall condition with schizophrenia in Indonesia, particularly when the respondents in this study were recruited from outpatient settings. This is why further research in the inpatient setting is required, with larger-scale testing is necessary for the future. Secondly, this study did not examine a long-term period of the patient's condition, which this way may ignore any changes during the therapy. Therefore, a longitudinal study is recommended to observe the instrument's effectiveness when dealing with changes over time, including changes in age, social characteristics, and cognitive development. Thirdly, further study is needed to evaluate the Indonesian version's criterion validity, which was not part of this study analysis.




Figure 2: Confirmatory factor analysis of IM-SWN (n = 108). *PF=physical function; MF=mental function; SC=self-control; ER=emotion regulation; IS=integration social. CFI=0.871; GFI=0.787; RMSEA=0.79

Conclusions

This study highlighted that the IM-SWN is a valid and reliable instrument for measuring well-being among the Indonesian population with schizophrenia under neuroleptic treatment.

Acknowledgments: The authors thanked the head and all staffs of the Menur National Mental Hospital Indonesia and Indonesian Community Care for Schizophrenia for providing supports and facilitating data collections. We also thanked participants of this study who have provided time and efforts for this study.

Research funding: The authors thanked the Indonesian Endowment Fund for Education and Universitas Airlangga for supporting this study.

Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Competing interests: Authors stated no conflict of interest.

Informed consent: Informed consent was obtained from all individuals included in this study.

Ethical approval: Ethical approval was obtained from the Research Ethics Committee of Menur Mental Hospital Surabaya, East Java, Indonesia with number 070/7556/305/2019.

References

1. Bullinger M, Quitmann J. Quality of life as patient-reported outcomes: principles of assessment. *Dialogues Clin Neurosci* 2014;16:137–45.

2. Karow A, Wittmann L, Schöttle D, Schäfer I, Lambert M. The assessment of quality of life in clinical practice in patients with schizophrenia. *Dialogues Clin Neurosci* 2014;16:185–95.
3. The WHOQOL Group. The world health organization quality of life assessment (WHOQOL). *Soc Sci Med* 1995;41:1403–9.
4. Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bousoño M. Quality of life in schizophrenic patients. *Dialogues Clin Neurosci* 2007;9:215–26.
5. Camfield L, Skevington SM. On subjective well being and quality of life. *J Health Psychol* 2008;13:764–75.
6. Heinrichs DH, Hanlon TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. *Schizophr Bull* 1984;10:388–98.
7. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. *Am J Psychiatr* 1997;154:457–65.
8. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. *J Clin Psychopharmacol* 1997;17:400–18.
9. Hamilton SH, Revicki DA, Genduso LA, Beasley CM. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double blind trial. *Neuropsychopharmacology* 1998;18:41–9.
10. Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders. Quality of life and clinical outcomes of a randomized clinical trial. *Qual Life Res* 1999;8:417–26.
11. Hamilton SH, Edgell ET, Revicki DA, Breir A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in European sample. *Int Clin Psychopharmacol* 2000;15:245–55.
12. Gureje O, Miles W, Keks N, Grainger D, Lamber T, McGrath J, et al. Olanzapine versus risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. *Schizophr Res* 2003;61:303–14.
13. Whitty P, Browne S, Clarke M, McTigue O, Waddington J, Kinsella T, et al. Systematic comparison of subjective and objective measures of quality of life at 4-year follow-up subsequent to a first episode of psychosis. *J Nerv Ment Dis* 2004;71:137–44.
14. Naber D. A self-rating to measure subjective effects of neuroleptic drugs. Relationships to objective psychopathology, quality of life, compliance and other clinical variables. *Int Clin Psychopharmacol* 1995;10(3 Suppl):133–8.
15. Naber D, Moritz S, Lambert M, Rajonk F, Holzbach R, Mass R, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. *Schizophr Res* 2001;50:79–88.
16. De Haan L, Weisfelt M, Dingemans PMAJ, Linszen DH, Wouters L. Psychometric properties of the subjective well-being under neuroleptics scale and the subjective deficit syndrome scale. *Psychopharmacology* 2002;162:24–8.
17. Kluge M, Wehmeier PM, Dittmann RW, Langer F, Czekalla J, Lehmann M, et al. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. *Pharmacopsychiatry* 2005;38:6–12.
18. Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kuhn KU, et al. Randomized double blind comparison of olanzapine vs clozapine on subjective well-being and clinical outcomes in patients with schizophrenia. *Acta Psychiatr Scand* 2005;111:106–15.
19. Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. *J Clin Psychiatr* 2006;67:1690–7.
20. Vothknecht S, Schoevers RA, de Haan L. Subjective well-being in schizophrenia as measured with the subjective well-being under neuroleptic treatment scale: a review. *Aust N Z Collage of Psychiatr* 2011;45:182–92.
21. Balestrieri M, Giaroli G, Mazzi M, Bellantuono C. Performance of the Italian version of the subjective well-being under neuroleptic (SWN) scale in schizophrenic outpatients. *Pharmacopsychiatry* 2006;39:81–4.
22. Siamouli M, Moutou K, Pantoula E, Magiria S, Chatzivasileiou I, Arapidis K, et al. Preliminary data concerning the reliability and psychometric properties of the Greek translation of the 20-item Subjective Well-Being under Neuroleptic Treatment Scale (SWN-20). *Ann Gen Psychiatr* 2009;8:3.
23. Pazvantoglu O, Simsek OF, Aydemir O, Sarisoy G, Korkmaz IZ, Mor S, et al. Reliability and validity of subjective well-being under neuroleptics scales-short form Turkish version. *Bull Clin Psychopharmacol* 2012;22:235–43.
24. Haring L, Mottus R, Jaanson P, Pilli R, Magi K, Maron E. Subjective well-being under neuroleptics scale short form (SWN-K): reliability and validity in an Estonian speaking sample. *Ann Gen Psychiatr* 2013;12:28.
25. Sanjuan J, Haro JM, Maurino J, Diez T, Ballesteros J. Validation of the Spanish version of the subjective well-being under neuroleptic (SWN) scale in patients with schizophrenia. *Med Clin* 2012;25:151–4.
26. Guo J, Zhao Z, Ha S. Testing the reliability and validity of Chinese version of subjective well-being under neuroleptics (SWN) short form. *Med J Chin People Health* 2003;15:1–2.
27. Yoon JS, Kook SH, Lee HY, Lee C, Paik IH. The development of a Korean modification of the scale to measure subjective well-being under neuroleptic treatment (KmSWN). *J Korean Neuropsychiatr Assoc* 2000;39:987–98.
28. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. Principles of good practice for translation and cultural adaptation process for Patient-Report Outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. *Value Health* 2005;8:94–104.
29. Bullinger M. Generic quality of life assessment in psychiatry. Potentials and limitations. *Eur Psychiatr* 1997;12:203–9.
30. Karow A, Naber D. Subjective well-being and quality of under atypical antipsychotic treatment. *Psychopharmacol* 2002;162:3–10.
31. Lambert M, Schimmelmann BG, Karow A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs-concepts, measurement and clinical relevance. *Pharmacopsychiatry* 2003;36:181–90.

32. Lambert M, Naber D, Schacht A, Wagner T, Hundemer HP, Karow A, et al. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. *Acta Psychiatr Scand* 2008;118:220–9.
33. Lambert M, Schimmelmann BG, Schacht A, Karow A, Wagner T, Wehmeier PM, et al. Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and relation to recovery criteria in 2842 patients followed over 3 years. *Schizophr Res* 2009;107:165–72.
34. Wehmeier PM, Kluge M, Schneider E, Schacht A, Wagner T, Schreiber W. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. *Prog Neuro-Psychopharmacol Biol Psychiatr* 2007;31:703–12.

also developed by scimago:



SCIMAGO INSTITUTIONS RANKINGS

SJR

Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name

[Home](#)[Journal Rankings](#)[Country Rankings](#)[Viz Tools](#)[Help](#)[About Us](#)

Journal of Basic and Clinical Physiology and Pharmacology

COUNTRY

[Germany](#)Universities and research
institutions in Germany

Media Ranking in Germany

SUBJECT AREA AND CATEGORY

[Biochemistry, Genetics and Molecular
Biology](#)
[Physiology](#)[Medicine](#)[Medicine \(miscellaneous\)](#)[Pharmacology, Toxicology and
Pharmaceutics](#)[Drug Discovery](#)[Pharmacology](#)

PUBLISHER

[Walter de Gruyter GmbH](#)

H-INDEX

36

PUBLICATION TYPE

[Journals](#)

ISSN

07926855, 21910286

COVERAGE


1985-1988, 1990-2021

INFORMATION

[Homepage](#)[How to publish in this journal](#)m.horowitz@mail.huji.ac.il

SCOPE


The Journal of Basic and Clinical Physiology and Pharmacology (JBCPP) is a peer-reviewed bi-monthly published journal in experimental medicine. JBCPP publishes novel research in the physiological and pharmacological sciences, including brain research; cardiovascular-pulmonary interactions; exercise; thermal control; haematology; immune response; inflammation; metabolism; oxidative stress; and phytotherapy. As the borders between physiology, pharmacology and biochemistry become increasingly blurred, we also welcome papers using cutting-edge techniques in cellular and/or molecular biology to link descriptive or behavioral studies with cellular and molecular mechanisms underlying the integrative processes. Topics: Behavior and Neuroprotection, Reproduction, Genotoxicity and Cytotoxicity, Vascular Conditions, Cardiovascular Function, Cardiovascular-Pulmonary Interactions, Oxidative Stress, Metabolism, Immune Response, Hematological Profile, Inflammation, Infection, Phytotherapy.

 Join the conversation about this journal

 Quartiles


FIND SIMILAR JOURNALS options 

1 Archives of Physiology and Biochemistry GBR 65% similarity	2 International Journal of Pharmacology PAK 62% similarity	3 Pathophysiology CHE 60% similarity	4 Tropical Journal of Pharmaceutical Research NGA 60% similarity	5 Iranian Journal of Basic Medical Sciences IRN 59% similarity
---	---	---	---	---



Journal of Basic and Clinical Physiology and...

Q3 Drug Discovery
best quartile

SJR 2021
0.35

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com" >
```

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool**.

Metrics based on Scopus® data as of April 2022

O **Oman** 3 years ago

How much money to publis in this journal

reply

Melanie Ortiz 3 years ago

Dear Oman,
thank you for contacting us.
Unfortunately, we cannot help you with your request, we suggest you visit the journal's homepage or contact the journal's editorial staff , so they could inform you more deeply.
Best Regards, SCImago Team

D **Daniel Orieko** 3 years ago

Please how do you get original article submitted.

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Daniel, thank you very much for your comment, we suggest you look for author's instructions/submission guidelines in the journal's website. Best Regards, SCImago Team

D **dr jhanvi vaghela** 3 years ago

Is Journal of Basic and Clinical Physiology and Pharmacology is online only journal ??

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Jhanvi,
thank you for contacting us.
Sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus.
Unfortunately, we cannot help you with your request, we suggest you to visit the journal's homepage or contact the journal's editorial staff, so they could inform you more deeply.
Best Regards, SCImago Team

N **Nilufar** 3 years ago

Dear Sir/Madam,

I couldn't find how to publish the article at this journal. Could you possibly send the requirements of publishing at this journal, please?

Kindest regards,
Nilufar

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Nilufar,

You can see the updated information just above. Best Regards, SCImago Team

Leave a comment

Name

Email

(will not be published)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS
Herato (Saire 1.1) (00)

[Cookie settings](#)

[Cookie policy](#)



Source details

Journal of Basic and Clinical Physiology and Pharmacology

CiteScore 2021

2.5



Formerly known as: Reviews in Clinical and Basic Pharmacology

Scopus coverage years: from 1985 to 1988, from 1990 to Present

Publisher: Walter de Gruyter

SJR 2021

0.347



ISSN: 0792-6855 E-ISSN: 2191-0286

Subject area: Pharmacology, Toxicology and Pharmaceutics: Pharmacology

Pharmacology, Toxicology and Pharmaceutics: Drug Discovery View all

SNIP 2021

0.728



Source type: Journal

[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021

$$2.5 = \frac{1,062 \text{ Citations 2018 - 2021}}{421 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022

$$3.6 = \frac{1,527 \text{ Citations to date}}{429 \text{ Documents to date}}$$

Last updated on 05 April, 2023 • Updated monthly

CiteScore rank 2021

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#203/303	33rd
Pharmacology		
Pharmacology, Toxicology and Pharmaceutics	#109/154	29th
Drug Discovery		

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)

About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

ELSEVIER

[Terms and conditions ↗](#) [Privacy policy ↗](#)

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.





**KOMITE ETIK PENELITIAN KESEHATAN (KEPK)
RUMAH SAKIT JIWA MENUR PROVINSI JAWA TIMUR**

KETERANGAN KELAIKAN ETIK

ETHICAL APPROVAL

No. 070 *1756* /305/2019

KOMITE ETIK PENELITIAN KESEHATAN (KEPK) RS JIWA MENUR PROVINSI JAWA TIMUR TELAH MEMPELAJARI SECARA SEKSAMA PROTOKOL PENELITIAN YANG DIUSULKAN, MAKA DENGAN INI MENYATAKAN BAHWA PENELITIAN BERJUDUL:

"Analisis Efektivitas Biaya Terapi Antipsikotik Sebagai Implementasi Asuhan Kefarmasian Pada Pasien *Skizofrenia*"

Peneliti Utama : Julaeha
NIM : 051617097311
Institusi : Prodi S3 Farmasi
Universitas Airlangga
Unit/Lembaga/Tempat Penelitian : Rumah Sakit Jiwa Menur Provinsi Jawa Timur.

DINYATAKAN LAIK ETIK

Surabaya, 20 Oktober 2019
DIREKTUR RUMAH SAKIT JIWA MENUR
PROVINSI JAWA TIMUR


dr. Herlin Ferliana, M.Kes

Pembina Utama Muda
NIP. 19640621 199011 2 001